TriangleBlinatumomab (NCT07227584)
Blinatumomab trial for Acute Lymphoblastic Leukemia (NCT07227584). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for people aged 18 to under 51 with newly-diagnosed Philadelphia-negative acute lymphoblastic leukemia or eligible lymphoblastic lymphoma. Mixed-phenotype leukemia and prior induction treatment are allowed.
The idea: multi-drug chemotherapy is given in stages, including treatment into spinal fluid. CD19-positive B-ALL treatment includes blinatumomab, which links cancer cells to T cells. The T-cell regimen differs. Researchers assess treatment completion and safety. Treatment lasts about two years, followed by eight years of follow-up.
This phase 2 study plans 67 patients. Marlise Luskin leads at Dana-Farber in Boston, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.